Treating sexual dysfunction

Abstract

The present disclosure describes use of oxytocin, in combination with one or more other agents as described herein, for use for example in the treatment of certain conditions.

1 .- 14 . (canceled) 
     
     
         15 . A method comprising administering to a subject suffering from sexual dysfunction a composition comprising oxytocin by a first route of administration, wherein the subject has received or is receiving a 5-HT1A agonist by a second, different route of administration, so that the subject receives combination therapy with both. 
     
     
         16 . The method of  claim 15 , wherein the sexual dysfunction is (i) delayed orgasm and/or (ii) difficulty achieving orgasm and is secondary to current and/or prior use of psychotropic medications. 
     
     
         17 . The method of  claim 15 , wherein the composition comprising oxytocin is administered intranasally, orally, sublingually, or topically. 
     
     
         18 . The method of  claim 15 , wherein the 5-HT1A agonist is administered intranasally, orally, sublingually, or topically. 
     
     
         19 . The method of  claim 15 , wherein the step of administering comprises administering both the composition comprising oxytocin and the 5-HT1A agonist to the subject. 
     
     
         20 . The method of  claim 19 , wherein the composition comprising oxytocin is administered prior to the 5-HT1A agonist. 
     
     
         21 . The method of  claim 19 , wherein the 5-HT1A agonist is administered prior to the composition comprising oxytocin. 
     
     
         22 . The method of  claim 15 , wherein the 5-HT1A agonist is a 5-HT1A partial agonist. 
     
     
         23 . The method of  claim 22 , wherein the 5-HT1A partial agonist is buspirone. 
     
     
         24 . The method of  claim 15 , wherein the 5-HT1A agonist is a full agonist. 
     
     
         25 . The method of  claim 15 , wherein the subject is a woman. 
     
     
         26 . The method of  claim 25 , wherein the subject is a post-menopausal woman. 
     
     
         27 . The method of  claim 15 , wherein the subject is a male. 
     
     
         28 . The method of  claim 15 , wherein the step of administering the composition comprising oxytocin occurs approximately 5 minutes to six hours prior to sexual activity. 
     
     
         29 . The method of  claim 28 , wherein the step of administering the at least one sublingual 5-HT1A partial agonist occurs approximately 30 minutes to 120 minutes, 30 minutes to 60 minutes, or 5 minutes to 20 minutes prior to sexual activity. 
     
     
         30 . The method of  claim 15 , further comprising administration of at least one additional agent that (i) modulates one or more of parasympathetic activity, sympathetic activity, or oxytocin secretion and/or (ii) can act as a contextual modifier to augment biological activity of oxytocin. 
     
     
         31 . The method of  claim 30 , wherein the at least one additional agent is administered prior to, subsequent to, or concomitant with (i) the intranasal oxytocin; and/or (ii) the at least one sublingual 5-HT1A partial agonist. 
     
     
         32 . A method comprising administering to a subject suffering from sexual dysfunction 5-HT1A agonist by a first route of administration, wherein the subject has received or is receiving a composition comprising oxytocin by a second, different route of administration, so that the subject receives combination therapy with both. 
     
     
         33 . The method of  claim 32 , wherein the sexual dysfunction is (i) delayed orgasm and/or (ii) difficulty achieving orgasm and is secondary to current and/or prior use of psychotropic medications. 
     
     
         34 . The method of  claim 32 , wherein the composition comprising oxytocin is administered intranasally, orally, sublingually, or topically. 
     
     
         35 . The method of  claim 32 , wherein the 5-HT1A agonist is administered intranasally, orally, sublingually, or topically. 
     
     
         36 . The method of  claim 32 , wherein the 5-HT1A agonist is a 5-HT1A partial agonist. 
     
     
         37 . The method of  claim 36 , wherein the 5-HT1A partial agonist is buspirone. 
     
     
         38 . The method of  claim 32 , wherein the 5-HT1A agonist is a full agonist. 
     
     
         39 . The method of  claim 32 , wherein the subject is a woman. 
     
     
         40 . The method of  claim 39 , wherein the subject is a post-menopausal woman. 
     
     
         41 . The method of  claim 32 , wherein the subject is a male. 
     
     
         42 . The method of  claim 32 , further comprising administration of at least one additional agent that (i) modulates one or more of parasympathetic activity, sympathetic activity, or oxytocin secretion and/or (ii) can act as a contextual modifier to augment biological activity of oxytocin.